Cetera Advisors’s BlackRock Health Sciences Trust BME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-14,640
Closed -$666K 1379
2022
Q1
$666K Sell
14,640
-3,495
-19% -$155K 0.01% 765
2021
Q4
$880K Sell
18,135
-1,036
-5% -$49K 0.02% 655
2021
Q3
$913K Buy
19,171
+1,036
+6% +$50.5K 0.02% 636
2021
Q2
$880K Buy
18,135
+2,378
+15% +$114K 0.02% 597
2021
Q1
$729K Buy
15,757
+654
+4% +$31K 0.02% 591
2020
Q4
$719K Hold
15,103
0.02% 505
2020
Q3
$647K Sell
15,103
-2,276
-13% -$97.4K 0.02% 476
2020
Q2
$709K Hold
17,379
0.03% 442
2020
Q1
$627K Buy
17,379
+1,625
+10% +$64.8K 0.03% 417
2019
Q4
$669K Buy
15,754
+6,667
+73% +$264K 0.03% 463
2019
Q3
$348K Buy
+9,087
New +$350K 0.02% 648

Other funds holding BME

Cetera Advisors's BME Position: Q2 2022 in Review

Cetera Advisors sold out of BlackRock Health Sciences Trust (BME) in Q2 2022, closing a stake of 14,640 shares — an estimated $666K sold.

Cetera Advisors first reported a position in BME in Q3 2019 and held it in 11 quarters. The position peaked at $913K in Q3 2021. 62 funds tracked by Wall St. Rank hold BME as of Q2 2022.

  • Cetera Advisors reported no remaining BlackRock Health Sciences Trust position as of Q2 2022 after selling out during the quarter.
  • Cetera Advisors sold 14,640 BlackRock Health Sciences Trust shares in Q2 2022, an estimated $666K.
  • Cetera Advisors first reported a position in BlackRock Health Sciences Trust in Q3 2019 and held it in 11 quarters.
  • Cetera Advisors's BlackRock Health Sciences Trust position peaked at $913K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held BlackRock Health Sciences Trust as of Q2 2022.

Based on Cetera Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.